Aquestive Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Aquestive Therapeutics

03/03/2025 21:35

Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to show a rise in quarterly revenue when it reports  results on March 5 for the period ending December 31 2024

The Warren New Jersey-based  company is expected to report a 19.0% increase in revenue to $13.083 million from $11 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aquestive Therapeutics Inc is for a loss of 14 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $10.00​, above​ its last closing price of $2.80. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.13
-0.13
Met
-2.6
Jun. 30 2024
-0.13
-0.12
-0.03
Beat
75.8
Mar. 31 2024
-0.08
-0.08
-0.17
Missed
-106.5​
Dec. 31 2023
-0.08
-0.08
-0.11
Missed
-37.5
​​Sep. 30 2023
-0.11
-0.11
-0.03
Beat
73.5
Jun. 30 2023
-0.12
-0.12
-0.10
Beat
15.3​
Mar. 31 2023
-0.18
-0.19
-0.12
Beat
36.5
Dec. 31 2022
-0.21
-0.23
-0.23
Met
0.3

This summary was machine generated March 3 at 21:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)